FRI, OCT 8TH, 2021 11:00 CET


RLS Global AB provides livestream strategy update focusing on the global collaboration with ConvaTec Ltd

RLS long term vision is to be a leading research driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as burns and dermatology. In order to maximize our patient reach, RLS intends to work with partners to commercialize its products globally. RLS is confident in the company’s platform technology and its unique features and what this can bring to patients around the world.

Thursday, October 14th at 09:00 am CET, RLS will present a strategy update focusing on the company’s platform, the recently established global collaboration with ConvaTec Ltd and new research project within the company. The presentation is followed by a question-and-answer session led by Redeye’s analyst Erik Nordström.

RLS CEO, Karin Fischer, will lead the presentation together with Susanne Olausson, CTO, and Magnus Nolmark, COO. Additional participant is also Roland Frösing, MD, PhD and board member.

The presentation will be held in English.

For more information and registration: Click here


RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email:
During the period 2012–2017, the company was listed on Aktietorget.


Karin Fischer, CEO
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
Telephone: +46 0730 23 13 57


About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company’s unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: Read more at